CAI
Clinical Asset Index
by VOS Supply Group
Drugs · acquisition-cost intelligence

Aspirin and Extended - Release Dipyridamole Capsules, 25 mg / 200 mg

Aspirin and Dipyridamole· ingredient aspirinOther agents for local oral treatment· ASPIRIN 25 mg/1; DIPYRIDAMOLE 200 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$0.57275
NADAC — pharmacy acquisition cost, not a retail/cash price

Acquisition-cost history

Weekly NADAC per EA — the trend nobody else shows. 6 weeks.

2025-12-172026-05-20

Same-ingredient options by acquisition cost

Other aspirin products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.

ProductNADAC / EAvs this
adult low dose aspirin$0.01438−$0.55840
Aspirin$0.01601−$0.55670
Aspirin$0.02233−$0.55040
Adult Chewable Aspirin$0.02595−$0.54680
AeroTab Pain Reliever$0.04346−$0.52930
ACETAMINOPHEN ASPIRIN AND CAFFEINE$0.06716−$0.50560
butalbital, aspirin, and caffeine$0.97831+$0.40560
Ascomp with Codeine$1.09+$0.51460

Medicare Part D coverage · CY2026

On 319 plan formularies · typical tier 4
Prior auth 0% · Step therapy 0% · Quantity limit 23% of formularies

Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.